公司资料
Rallybio 股价、新闻与催化剂
- 股票代码:
- RLYB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
16.93 USD (-1.51%)
收盘价
最后更新: 2026年9月21日
94.1M USD
市值
股价为何变动
截至 2026年9月21日，RLYB 下跌 1.51%，收于 $16.93。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Rallybio sits in specialty biotechnology.
商业模式特征
The business depends on clinical proof, pipeline selection, and the ability to create value in rare-disease markets.
生物医药行业定位
Rallybio is a rare-disease catalyst name whose valuation is closely linked to proof-of-concept and strategy.
未来催化剂
- Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path. The stock tends to respond quickly if the next update shows the platform still has room to run.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。